Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

44 results about "Medications therapy" patented technology

Method of pairing therapy devices using shared secrets, and related systems, methods and devices

Systems, methods and devices are described for establishing trusted connections among two or more therapy devices that form, or form part of, a medication therapy system. A medication delivery electronics may include a first communication interface, a connection manager, and a therapy management application. A first communication interface may be configured to establish and communicate over one or more communication links. A connection manager may be configured to generate a candidate shared secret key and provide the shared key to a first therapy device over a first communication link established by a first communication interface. A candidate shared key may be generated responsive to one or more shared secret parameters. A therapy management application may be configured to receive, using the first communication interface, the first therapy related information from the first therapy device over a first trusted communication link established by the first communication interface responsive to acceptance of a candidate shared secret.
Owner:BIGFOOT BIOMEDICAL INC

System for monitoring and delivering medication to apatient and method of using the same to minimize the risks associated with automated therapy

A system and method for monitoring and delivering medication to a patient. The system includes a controller that has a control algorithm and a closed loop control that monitors the control algorithm. A sensor is in communication with the controller and monitors a medical condition. A rule based application in the controller receives data from the sensor and the closed loop control and compares the data to predetermined medical information to determine the risk of automation of therapy to the patient. A system monitor is also in communication with the controller to monitor system, remote system, and network activity and conditions. The controller then provides a predetermined risk threshold where below the predetermined risk threshold automated closed loop medication therapy is provided. If the predetermined risk threshold is met or exceeded, automated therapy adjustments may not occur and user / clinician intervention is requested.
Owner:ICU MEDICAL INC

Removable lung isolation device for localized drug therapy

A system and method of applying therapy to a patient including navigating a dual lumen catheter to a desired segmental bronchus, inflating a balloon located on a distal portion of the catheter via a first tube of the dual lumen catheter to isolate the segmental bronchus, injecting a therapeutic medium into the isolated segmental bronchus via a second tube of the dual lumen catheter, and retracting the dual lumen catheter to leave the balloon indwelling, wherein the balloon retains the injected therapeutic medium in the isolated segmental bronchus.
Owner:COVIDIEN LP

Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices

A mobile computing device for providing medication therapy recommendations includes a secure execution environment having one or more services executing therein. One service of the one or more services is configured to establish a secure user interaction process at the mobile computing device. The mobile computing device includes a normal execution environment having a medication therapy application executing therein. The medication therapy application is configured to determine at least one medication delivery instruction, request confirmation of the delivery instruction using the secure user interaction process, and provide certified medication delivery instructions to a communications interface configured for communication with a medication delivery unit responsive to a confirmation result. The confirmation result is received, at least in part, responsive to the secure user interaction process.
Owner:BIGFOOT BIOMEDICAL INC

Tamoxifen curative effect prediction related SNP (Single Nucleotide Polymorphism) site detection primer group and kit based on nucleic acid mass spectrum platform

The invention discloses a tamoxifen curative effect prediction related SNP site detection primer group and a kit based on a nucleic acid mass spectrum platform, which are designed aiming at four gene mutation sites, namely C10ORF11, CYP19A1, CYP2D6 and CYP2D6 * 10, related to tamoxifen curative effect prediction, specific detection of site mutation related to tamoxifen curative effect prediction can be realized through one detection hole, the accuracy is high, the detection time is short, the detection time is short, and the detection efficiency is high. The detection period can be greatly shortened, and the detection cost is reduced; in addition, the method can be applied to a nucleic acid mass spectrum platform to realize detection of multiple gene loci, and provides reference for individualized tamoxifen drug therapy.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Micro-robot cluster capable of simultaneously delivering multiple drugs in targeted manner and preparation method of micro-robot cluster

The invention provides a micro-robot cluster capable of simultaneously delivering multiple drugs in a targeted manner and a preparation method thereof. The micro-robot cluster comprises a plurality of micro-robots, and each micro-robot sequentially comprises a magnetic nanoparticle, a hydrogel layer and a pH response material shell from inside to outside; the hydrogel layer comprises dopamine (PDA) grafted 3-(methacryloyloxy) propyl trimethoxy silane located on the inner side and methacrylic acid wrapping the outer layer of the hydrogel layer; the hydrogel layer is used for packaging a plurality of medicines. According to the technical scheme, the micro-robot cluster can be driven by an external magnetic field to be conveyed to a specific position in a targeted mode in a complex simulated blood environment, combined delivery and controllable release of various drugs are achieved, and the micro-robot cluster has the advantages of being high in targeting performance, high in drug carrying capacity, intelligent in release and the like and can be applied to the field of precise drug therapy.
Owner:HARBIN INSTITUTE OF TECHNOLOGY (SHENZHEN) (INSTITUTE OF SCIENCE AND TECHNOLOGY INNOVATION HARBIN INSTITUTE OF TECHNOLOGY SHENZHEN)

Application of substance for increasing content or activity of OSKM in prevention of articular cartilage senescence and treatment of osteoarthritis disease

The invention discloses an application of a substance for increasing the content or activity of OSKM in preventing articular cartilage senescence and treating osteoarthritis diseases. The OSKM provided by the invention is obtained by connecting Oct4, Sox2, Klf4 and C-Myc. Experiments prove that OSKM or a substance for increasing the content or activity of OSKM has a definite effect in preventing cartilago articularis senescence and treating osteoarthritis diseases, and a new strategy is provided for developing gene therapy for preventing cartilago articularis senescence and treating osteoarthritis diseases. And the selectable range of clinical gene therapy and drug therapy is expanded.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Infusion pump and method to prevent titration errors in infusion therapies

An infusion pump including an interface unit for receiving first data for a first infusion regimen for a medication, the first regimen including a first unit of measure in which the first regimen is executed and after receipt of the first data, second data for a second infusion regimen for the medication, the second regimen including a second unit of measure in which the second regimen is executed. The pump also includes a processor for comparing the first and second units of measure. In one embodiment, the pump includes a graphical user interface, and the processor identifies a difference between the first and second units of measure; generates, using the processor, a warning message; and displays the message on the graphical user interface. In another embodiment, the processor holds in abeyance initiation of the second infusion regimen in response to identifying the difference between the units of measure.
Owner:BAXTER INT INC +1

Wearable medication adherence and patient monitoring device

A wearable device for wearing by a patient in receipt of medication, comprising components of a medication and patient monitoring unit (MPMU) including: an interactive visual display unit (VDU), an interactive audio platform (AP) and a plurality of sensor units (SUs); and comprising components of an operating unit (OU) including: a processing unit (CPU) and memory, a wireless communication unit (WCU), a power supply unit (PSU) and an energy storage unit (ESU) wherein a plurality of sensor units comprises at least one dehydration sensor unit (DHSU).
Owner:PRICE DAWN

Coordinated electrical and drug therapies

A method includes providing one of electrical therapy or drug therapy to a recipient to treat a condition of the recipient, monitoring an efficacy of the provided electrical therapy or drug therapy in treating the condition of the recipient, and controlling the other of the electrical therapy or the drug therapy based on the monitoring.
Owner:COCHLEAR LIMITED

Human omic-driven machine learning methods and systems for evaluating patient safety

A computer-implemented method of estimating a risk associated with patient safety is disclosed. One or more computers execute processing comprising receiving a training data set comprising drug-associated patient safety data and human omics data. One or more probabilistic features from the training data set are identified, where the one or more probabilistic features comprise human omics features associated with a drug therapeutic. A ground truth label associated with the drug therapeutic and comprising a positive or a negative patient safety outcome corresponding to the one or more probabilistic features is derived. The method trains one or more machine learning models in accordance with the ground truth label and applies the trained machine learning models to a patient dataset of human omics data to generate a calculated indication of a positive or a negative patient safety outcome. The method takes one or more actions in response to the calculated indication.
Owner:JANSSEN RESEARCH & DEVELOPMENT LLC

Use of methyl parahydroxybenzoate and its sodium salt in anti-coronavirus

The present invention belongs to the field of drug therapy, and specifically relates to the use of methyl parahydroxybenzoate and its sodium salt in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of methyl parahydroxybenzoate, its sodium salt and its inhalation preparation in the treatment of coronavirus infectious diseases. By verifying the new use of methyl parahydroxybenzoate and its sodium salt inhalation solution in a mouse test infected with human coronavirus HCoV-229E, the technical solution has novelty, and an efficacy test of meta-cresol inhalation solution in treating pneumonia caused by HCoV-229E virus infection was conducted. The results showed that methyl parahydroxybenzoate and its sodium salt inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.
Owner:INCREASEPHARM HENGQIN INST CO LTD

Methods of treating antibody-mediated rejection with TACI-Fc fusion proteins

The present invention relates to drugs, dosage regimens, dosing intervals, and methods of administration for treating antibody-mediated rejection using an effective amount of a drug targeting Blys and / or APRIL. The result shows that the provided effective dose of the drug targeting Blys and / or APRIL shows good safety and treatment effect in the process of preventing, treating or relieving antibody-mediated rejection in patients who are about to accept, are receiving or have accepted entity organ transplantation.
Owner:REMEGEN CO LTD

NO donor coumarin Mannich base compounds and preparation method and use thereof

The present invention relates to NO donor type coumarin Mannich base compounds and preparation methods and uses thereof, and belongs to the field of pharmaceutical chemistry and pharmacotherapy. The method comprises using resorcinol as a raw material and reacting multiple people to obtain a lead compound 7-hydroxy-coumarin-3-ethyl formate; the obtained lead is then reacted with paraformaldehyde and an organic amine by Mannich reaction to obtain an intermediate 7-hydroxy-8-aminomethyl-coumarin-3-ethyl formate; then hydrolyzed to obtain 7-hydroxy-8-aminomethyl-coumarin-3-formic acid; 7-hydroxy-8-aminomethyl-coumarin-3-formic acid reacts with aminofurazan / hydroxyfurazan under the action of an ester condensation reagent to obtain an NO donor type coumarin Mannich base compound. The present invention introduces an aminomethyl Mannich base at the ortho position of the 7-hydroxyl group of coumarin, and introduces an NO donor at the C-3 position, thereby improving the anti-tumor activity of the lead compound, improving its water solubility, and giving it good drugability.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Catheter for delivery of drug therapy to remote site in body

The tubular catheter wall of the catheter (1) comprises a random skeleton (7) having a micromachined cutting pattern (7A), the overall skeleton resection rate being between 40% and 90%. A random skeleton (7) arranged between the inner liner and the outer laminate comprises a plurality of mutually connected struts (21L-28L, 31L-38L, 21R-28R, 31R-38R). Each strut has a respective pair of two mutually opposed longitudinal strut edges (41, 42). Each strut edge (41, 42) has a random bend and / or a random tip, which makes each strut unique. Randomly shaped skeleton strut edges not only improve the mutual bonding among the skeleton, the liner and the outer laminate, but also improve the torsionality of the conduit, including the prevention of the occurrence of whip phenomena during twisting.
Owner:IMDS R&D

Stem cell and biological material compounded bone repair technology

The invention discloses a stem cell and biological material compounded bone repair technology, which ensures sufficient and high-quality stem cell supply by amplifying bone marrow mesenchymal stem cells and induced pluripotent stem cells from autologous and allogenic sources, optimizes the selection and surface treatment of biological materials, and improves the bone repair efficiency. The stem cell-biological material composite with proper pore size and mechanical property is prepared by using electrostatic spinning, 3D printing and jet printing technologies, a natural bone tissue structure is simulated, in-vitro induced differentiation is performed through an osteogenesis induction culture medium, a composite with osteogenesis potential is formed, the bone repair process is accelerated, and the bone repair effect is improved. In an operation, the complex subjected to induced differentiation is accurately implanted into bone defect and fracture parts, good integration is ensured, and the bone repair effect is comprehensively evaluated and promoted through regular imaging examination and biomechanical test in combination with drug therapy and rehabilitation training.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Removable lung isolation device for localized drug therapy

A system and method of applying therapy to a patient including navigating a dual lumen catheter to a desired segmental bronchus, inflating a balloon located on a distal portion of the catheter via a first tube of the dual lumen catheter to isolate the segmental bronchus, injecting a therapeutic medium into the isolated segmental bronchus via a second tube of the dual lumen catheter, and retracting the dual lumen catheter to leave the balloon indwelling, wherein the balloon retains the injected therapeutic medium in the isolated segmental bronchus.
Owner:COVIDIEN LP

Removable lung isolation device for topical drug therapy

A system and method of applying therapy to a patient includes navigating a dual lumen catheter to a desired segment of bronchus; inflating, via a first tube of the dual lumen catheter, a balloon located on a distal portion of the catheter to isolate the segment bronchial tube; injecting a therapeutic medium into the isolated segment bronchial tube via a second tube of the dual lumen catheter; and retracting the dual lumen catheter to leave the balloon indwelling, where the balloon retains the injected therapeutic medium in the isolated segment bronchial tube.
Owner:COVIDIEN LP

Use of substances increasing the content or activity of oskm in preventing aging of articular cartilage and treating osteoarthritic diseases

ActiveCN119792490BDiseasePharmaceutical drug
The application discloses application of a substance with increased OSKM content or activity in preventing joint cartilage aging and treating osteoarthritis diseases. The OSKM of the application is obtained by connecting Oct4, Sox2, Klf4 and C-Myc. The experiment of the application proves that the OSKM or the substance with increased OSKM content or activity has a definite effect in preventing joint cartilage aging and treating osteoarthritis diseases, the application provides a new strategy for developing gene therapy for preventing joint cartilage aging and treating osteoarthritis diseases, and expands the selectable range of clinical gene therapy and drug therapy.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Compositions and methods for detecting head and neck cancer

Disclosed are compositions and methods for detecting biomarkers for proteins, typically associated with head and neck cancer, or more particularly head and neck squamous cell carcinoma (HNSCC). Such markers may be used to allow an individual susceptible to HNSCC to manage their lifestyle and / or drug therapy to avoid further development of disease.
Owner:LABORATORY CORPORATION OF AMERICA HOLDINGS INC

Application of organoid in hepatic ischemia reperfusion injury

The invention relates to the field of regenerative medicine and tissue engineering, and provides application of a liver organoid in preparation of a medicine for treating liver ischemia reperfusion injury, the liver organoid realizes efficient transplantation and function integration of the organoid in an intraspleen injection mode, liver tissue injury caused by IRI is effectively improved, and the liver tissue injury is reduced. The repair and functional reconstruction of damaged tissues are promoted, the defects of the existing drug therapy and stem cell therapy are overcome, and a new path is developed for the treatment of liver diseases.
Owner:ZHEJIANG UNIV

Long-acting non-insulin dependent double-target recombinant protein and application thereof in diabetes treatment

The invention belongs to the technical field of biological medicines, and particularly relates to a long-acting non-insulin dependent double-target recombinant protein and application thereof in diabetes treatment. According to the present invention, the double-target recombinant protein is obtained by connecting the polypeptide of the targeted activation beta-Klotho / FGFR1c compound with the polypeptide of the targeted activation GLP-1 receptor through the linker; the double-target recombinant protein provided by the invention has a hypoglycemic effect, reduces the inflammation level of diabetes mellitus, effectively improves the blood sugar of diabetes mellitus, and can be used as a drug for treating and / or preventing diabetes mellitus and related diseases, protecting the structural integrity of liver cells of diabetes mellitus and reversing liver injury related to diabetes mellitus; the double-target recombinant protein provided by the invention is independent in hypoglycemic mechanism, different from insulin and non-insulin dependent hypoglycemic mechanism.
Owner:QIQIHAR UNIVERSITY

Medication therapy management system and methods

The invention relates generally to medication therapy and more particularly to a system and methods for medication therapy management to support improved adherence and alert clinicians of changes in behavior or symptoms. The system may facilitate interactions between various data sources (e.g., medical health records, genomics databases, and other connected third-party devices) to manage workflow, execute rules, interface with knowledge bases, codify information, schedule events, provide notification, and more. In addition, the system may include a conversational or actionable artificial intelligence persona tailored to each user and configured to, for example, converse, instruct, and / or coach a user according to one or more features of the system. Advantageously, the system may improve adherence and facilitate patient engagement, care transition, and disease management, resulting in, for example, reduced healthcare costs for providers and payers, and enhanced drug use for pharmaceutical manufacturers, pharmacies, and specialty pharmacies.
Owner:LEAP OF FAITH TECH

System for mimicking cellular microenvironment and method for evaluating cell development or drug therapy effectiveness using the same

A system for mimicking cellular microenvironment is provided and includes a chip, a hydrogel, and cells in contact with the hydrogel. The chip includes a first carrier having a pore and a second carrier coupled to the first carrier. The hydrogel is disposed in the pore and includes extracellular matrix. Also provided is a method for evaluating cell development, including providing the system for mimicking cellular microenvironment; providing a stimulation to a responsive hydrogel; and evaluating the cell development. Further provided is a method for evaluating drug therapy effectiveness, including providing the system for mimicking cellular microenvironment; administering the drug to the cells; and evaluating drug therapy effectiveness.
Owner:ANIVANCE AI CORP

Construction method and application of spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model

The invention provides a construction method and application of a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model. The spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model is obtained through expression deletion of Trp53 and Cdkn2a of a non-human animal. The non-human animal model prepared by the invention can be used as an ideal animal model for screening drug candidates, evaluating drug treatment effects, evaluating drug toxicological effects and researching esophageal precancerous lesions or pathogenesis of esophageal cancer.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Drug therapy delivery system and method

A drug delivery device is provided for metering delivery of a drug to ocular tissue over a period of time. The device (100) includes a tube (104), a microporous core (106), and a body portion (102) having an exterior surface (108) defining an interior reservoir (110). The outer surface defines a port (112) of the body portion, the port being arranged to facilitate a first passage of the medicament from the reservoir. The tubular length defines a second passage of the medicament from the first end to the second end of the tubular. The first end is coupled to the port to receive a first passage of medicament from the reservoir. The second end is disposed at a distance from the first end to deliver a drug to ocular tissue. A microporous core is disposed in the lumen along at least a portion of the length of the tube and has a porosity to meter a second passage of the medicament.
Owner:WL GORE & ASSOC INC

Therapeutic substance delivery device and delivery system based on interventional mode

The invention relates to a therapeutic substance delivery device and delivery system based on an intervention mode, and the therapeutic substance delivery device comprises an outer sheath which is of a tubular structure and is provided with a far end and a near end which are opposite to each other, and the outer sheath is internally provided with a therapeutic substance delivery channel; the tube assembly is movably arranged in the outer sheath; the plugging assembly comprises a first balloon and a second balloon which are sequentially arranged in the axis direction of the outer sheath and used for temporarily blocking blood flow, and the position between the first balloon and the second balloon is an expected therapeutic substance conveying position; the keeping assembly is used for keeping the blood vessel at the expected therapeutic substance conveying position in an expanded state, and the keeping assembly adopts one of the following structures: a, a support frame; and b, a light-emitting component. According to the interventional-mode-based therapeutic substance delivery device and delivery system provided by the invention, when drugs are delivered to an endothelial injury part, blood vessels are prevented from being shrunk, and drug therapy is carried out in a blood vessel stretching state, so that the treatment effect is better.
Owner:HANGZHOU MATRIX MEDICAL TECH CO LTD

Application of substance for increasing content or activity of SOX5 in preventing aging and treating aging-related degenerative diseases

The invention discloses an application of a substance for increasing the content or activity of SOX5 in preventing senescence and treating senescence-related degenerative diseases. The invention finds that SOX5 or a substance for increasing the content or activity of SOX5 has a clear effect in delaying senescence and treating osteoarthritis diseases, and has a clear effect in delaying senescence of mesenchymal precursor cells, mesenchymal stem cells and cartilage stem cells, and the mesenchymal stem cells are an important progenitor cell source of cartilage cells. The invention provides a new strategy for developing gene therapy for delaying senescence and osteoarthritis diseases, and enlarges the selectable range of clinical gene therapy and drug therapy.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1

Mutation detection primer group of MEIOB gene, antisense oligonucleotide targeting mRNA of MEIOB gene, small molecule drug aiming at MEIOB protein and application of small molecule drug

The invention relates to the technical field of gene detection and biological medicine, in particular to a MEIOB gene mutation detection primer group, an antisense oligonucleotide targeting mRNA of the MEIOB gene, a small molecule aiming at MEIOB protein, an analogue of the small molecule and application of the small molecule, and the found hMEIOB gene mutation site and the potential mutation site in the hMEIOB gene can be detected. The ASO molecule can bind to a transcription product of the MEIOB gene in a targeted manner to inhibit the expression of the transcription product. The MEIOB protein targeted chemical small molecule and the analogue thereof have the capability of inhibiting the combination of MEIOB and SPATA22, and can be used as a non-hormone male contraceptive. The small chemical molecule of the targeted MEIOB protein and the analogue thereof have the capability of inhibiting the protein level and cell proliferation of MEIOB in a tumor cell line with high expression of MEIOB, and can be used as a targeted drug for treating tumors with high expression of MEIOB.
Owner:WUHAN UNIV